Islet banking for transplantation in diabetes mellitus

Rg, Bretzel; Bj, Hering; Federlin, K.

doi:10.1016/0011-2240(88)90393-8

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This procedure is relatively safe, noninvasive (percutaneous puncture of the liver) and repeatable, and it is performed in several centers worldwide [11,12]. The major factors limiting the large-scale application of islet graft in diabetic patients receiving chronic immunosuppression for a kidney graft are 1) the low percentage of patients reaching insulin independence and a complete normalization of glucose homeostasis [10]; and 2) the limited survival of fully successful grafts.…”

Section: Methodsmentioning

confidence: 99%

“…The major factors limiting the large-scale application of islet graft in diabetic patients receiving chronic immunosuppression for a kidney graft are 1) the low percentage of patients reaching insulin independence and a complete normalization of glucose homeostasis [10]; and 2) the limited survival of fully successful grafts. Most diabetic patients receiving an islet graft achieve only partial function and a reduction of the pretransplant insulin requirement [11][12][13][14][15][16]; they are characterized by fasting C-peptide concentrations in the near-normal range, but frankly abnormal fasting glucose and glycosylated hemoglobin [11][12][13][14]. In the last decade, we [15,16] and others [17] found that protein and lipid metabolism had greater sensitivity to acutely infused insulin than did glucose metabolism, both in diabetes and uremia.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Immunosuppressive therapy in pancreas and islet transplant: Need for simultaneous assessment of insulin sensitivity and secretion

Benedini¹,

Caumo²,

Terruzzi³

et al. 2013

JDM

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Immunosuppressive therapy in pancreas and islet transplant: Need for simultaneous assessment of insulin sensitivity and secretion

Benedini¹,

Caumo²,

Terruzzi³

et al. 2013

JDM

View full text Add to dashboard Cite

show abstract

“…It has been suggested that islet transplantation will not only restore physiological control of glucose homeostasis but also might result in prevention of the long-term morbidity associated with IDDM (2)(3)(4)(5)(6). It has been shown previously in animal models of IDDM that islet transplantation blocked and sometimes reversed the progression of secondary complications such as nephropathy (2), retinopathy (3), and neuropathy (4).…”

mentioning

confidence: 99%

Anti-CD8 Abrogates Effect of Anti-CD4–Mediated Islet Allograft Survival in Rat Model

Seydel

Shizuru²,

Grossman³

et al. 1991

Diabetes

View full text Add to dashboard Cite

We studied the effects of anti-CD4 treatment of diabetic ACI rats on the induction of tolerance to allogeneic (Lewis) islet allografts. When given as a 4-day treatment regimen, OX38, a mouse anti-rat CD4 antibody, caused depletion of greater than 80% of CD4+ cells from the peripheral blood of treated rats. After induction of diabetes (a single high-dose bolus of streptozocin) and 3 days after the initiation of anti-CD4 immunotherapy, recipient ACI rats were transplanted with fully allogeneic (Lewis) islets of Langerhans via the portal circulation. These transplanted islets were capable of returning the anti-CD4-treated ACI recipients to normoglycemia, which was maintained indefinitely in the absence of further immunosuppression. In contrast, treatment of recipient rats with OX8, an anti-CD8 monoclonal antibody (MoAb), induced only a slight prolongation of graft survival (less than or equal to 30 days). Further characterization of the cellular requirements for the induction of long-term transplantation survival revealed that successful pretransplantation anti-CD4 therapy could be ablated by the coincident treatment of recipient rats with depleting levels of anti-CD8 MoAb. These data point to the necessity of a regulator CD8+ cell in the induction of anti-CD4-mediated transplantation survival in this rat model of islet transplantation.

show abstract

Rat pancreatic islet pretreatment with anti-MHC class II monoclonal antibodies and culture: in vitro MLIC test response does not predict islet allograft survival

et al. 1993

View full text Add to dashboard Cite

Antigen presenting cells (APC) expressing MHC class II antigens have been attributed with stimulatory capacity for initiating islet allograft rejection (direct pathway). Therefore, we evaluated the effect of pretreating isolated islets with different monoclonal antibodies against MHC class II antigens and complement, with and without culture at 22 degrees C or 37 degrees C, on MHC class II antigen expression, on the allogeneic proliferative response in the mixed lymphocyte islet culture (MLIC) and on islet allograft survival in adult rats. Experiments were performed in two different strain combinations incompatible for MHC class II antigens and either incompatible or compatible for MHC class I antigens, in order to elucidate further the impact of class I antigens on islet allograft rejection. In terms of class II antigen suppression, pretreatment with anti-MHC class II antibodies together with complement and a 5-day (37 degrees C) culture period proved most effective. After this procedure 92.7% of the islets of LEW rats and 91.1% of the islets of LEW.1WR2 rats were negative for MHC class II antigens, as demonstrated by indirect immunofluorescence. Transfer of successfully pretreated islets to a MLIC in vitro test system provoked a significantly reduced allogeneic T-cell proliferative response in the case of additional MHC class I disparity (ratio 1.3 vs 4.7) and a response as low as that of a syngeneic setting when stimulator islets and allogeneic responder lymphocytes shared MHC class I antigens (ratio 1.0 vs 1.6).(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract

Islet banking for transplantation in diabetes mellitus

Cited by 3 publications

References 0 publications

Immunosuppressive therapy in pancreas and islet transplant: Need for simultaneous assessment of insulin sensitivity and secretion

Immunosuppressive therapy in pancreas and islet transplant: Need for simultaneous assessment of insulin sensitivity and secretion

Anti-CD8 Abrogates Effect of Anti-CD4–Mediated Islet Allograft Survival in Rat Model

Rat pancreatic islet pretreatment with anti-MHC class II monoclonal antibodies and culture: in vitro MLIC test response does not predict islet allograft survival

Contact Info

Product

Resources

About